Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 1/2019

25.01.2019 | Editorial

Post-reproductive Health: Window of Opportunity for Preventing Comorbidities

verfasst von: Suvarna Satish Khadilkar

Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Post-reproductive health is a challenging issue as it is surrounded by many controversies. Menopausal hormone therapy (MHT) has witnessed a rise and fall over last several years. We do understand that comorbidities incidence rises beyond menopause and we need to prevent them. When MHT was used universally, the risk–benefit ratio became unfavorable. Hence, the use of MHT dropped drastically. But newer studies have introduced the concept of window of opportunity, wherein MHT does not have harmful effects, but in fact it will prevent comorbidities associated with menopause. This editorial focuses on the prevention of menopause- and MHT-related comorbidities.
Literatur
2.
Zurück zum Zitat Writing Group for the Women’s Health Initiative. Investigators risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–33.CrossRef Writing Group for the Women’s Health Initiative. Investigators risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–33.CrossRef
3.
Zurück zum Zitat Grady D, Brown JS, Vittinghoff E, et al. HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol. 2001;97:116–20.PubMed Grady D, Brown JS, Vittinghoff E, et al. HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol. 2001;97:116–20.PubMed
4.
Zurück zum Zitat Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.CrossRef Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.CrossRef
5.
Zurück zum Zitat Mosekilde L, Hermann AP, Beck-Nielsen H, et al. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas. 1999;31(3):207–19.CrossRefPubMed Mosekilde L, Hermann AP, Beck-Nielsen H, et al. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas. 1999;31(3):207–19.CrossRefPubMed
6.
Zurück zum Zitat Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;9(345):e6409.CrossRef Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;9(345):e6409.CrossRef
7.
Zurück zum Zitat Wolff EF, He Y, Black DM, et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). Fertil Steril. 2013;99(5):1385–91.CrossRefPubMedPubMedCentral Wolff EF, He Y, Black DM, et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). Fertil Steril. 2013;99(5):1385–91.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat De Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19:313–5.CrossRefPubMed De Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19:313–5.CrossRefPubMed
9.
Zurück zum Zitat Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–31.CrossRefPubMedPubMedCentral Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–31.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306–12.CrossRefPubMed Biglia N, Cagnacci A, Gambacciani M, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric. 2017;20(4):306–12.CrossRefPubMed
12.
Zurück zum Zitat Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab. 2015;100:524–34.CrossRefPubMed Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab. 2015;100:524–34.CrossRefPubMed
13.
Zurück zum Zitat Wharton W, Gleason CE, Miller VM, et al. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res. 2013;13(1514):12–7.CrossRef Wharton W, Gleason CE, Miller VM, et al. Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog). Brain Res. 2013;13(1514):12–7.CrossRef
14.
Zurück zum Zitat Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531–9.CrossRefPubMedPubMedCentral Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531–9.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Zeleke BM, Bell RJ, Billah B, et al. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertil Steril. 2016;105:149–55.CrossRefPubMed Zeleke BM, Bell RJ, Billah B, et al. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertil Steril. 2016;105:149–55.CrossRefPubMed
Metadaten
Titel
Post-reproductive Health: Window of Opportunity for Preventing Comorbidities
verfasst von
Suvarna Satish Khadilkar
Publikationsdatum
25.01.2019
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe 1/2019
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-019-01202-w

Weitere Artikel der Ausgabe 1/2019

The Journal of Obstetrics and Gynecology of India 1/2019 Zur Ausgabe

Presidential Address

Presidential Address

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.